glp 1 drugs and rheumatoid arthritis Glucagon-like peptide its receptor agonists for the treatment of rheumatic diseases Glucagon-like peptide-1 receptor agonists in

Eur J Clin Invest 1992

doi: 10.1053/j.ackd.2021.04.002

doi: 10.1080/14656566.2024.2343092

Medicares search for effective obesity treatments: diets are not the answer

However, several factors could accelerate a reversal: declining GLP-1 drug prices through manufacturer competition or government negotiation, improved adherence data from newer formulations, long-term outcomes studies demonstrating cardiovascular benefit that changes the cost-benefit analysis, and state legislative mandates requiring obesity treatment coverage

In contrast, treating obesity with GLP-1RA decreases cardiovascular risk and the possible mechanisms of cardioprotection achieved by this class of drugs are discussed